Datapoint: Kadmon Holdings Scores First FDA Approval
The FDA last week approved Kadmon Holdings’ Rezurock for the treatment of chronic graft-versus-host disease, making the drug both Kadmon’s first-ever FDA approved drug, and the first ROCK2 inhibitor in the graft-versus-host market basket. Among the most advantaged therapies for graft-versus-host disease are Johnson & Johnson and AbbVie’s Imbruvica, which holds covered or better status for 73% of all insured lives under the pharmacy benefit, Incyte Corp.’s Jakafi (72%) and Amgen’s Enbrel (70%).
SOURCE: MMIT Analytics, as of 7/19/21